Germany’s New Drug Register To Help Tackle Supply Shortages, But Larger EU Problem Looms
The new German drug register is designed to be a first step in tackling potential drug shortages on the domestic market, but it currently lacks effective solutions.
You may also be interested in...
Germany’s discount contracts have secured huge savings for health insurers and the government, but are forcing generics manufacturers to reduce portfolios or leave the market altogether.
The 11-member staff CDER devotes to drug shortages is moving to the Office of the Center Director and will report to Deputy Director for Regulatory Programs Doug Throckmorton.
The Greater New York Hospital Association, in a meeting with FDA Commissioner Margaret Hamburg, says the agency should be more proactive when considering importation of unapproved drugs to mitigate a shortage.